Sigilon Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rogerio Vivaldi Coelho MBA
- Full Time Employees
- 62
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 4, 2020
- CIK
- 0001821323
- Website
- sigilon.com
- Similar Companies
- Business
- Sigilon Therapeutics, Inc. (SGTX) develops functional cures for chronic diseases through its Shielded Living Therapeutics (SLTx) platform, which encapsulates engineered cells in biocompatible spheres to deliver sustained therapeutic proteins while shielding against immune responses; the platform targets type 1 diabetes with SIG-002, a glucose-responsive islet cell replacement; hemophilia A with SIG-001, formerly in Phase I/II trials to prevent bleeding episodes; and lysosomal storage disorders including mucopolysaccharidosis type 1 (MPS1) via SIG-205, SIG-218, SIG-220, and SIG-005 for non-neurological manifestations, SIG-207 for Fabry disease, SIG-018 for MPS2, and SIG-020 for additional indications. Founded in 2015 and headquartered at 100 Binney Street, Suite 600, Cambridge, Massachusetts, the company operates as a subsidiary of Eli Lilly and Company following its acquisition in August 2023 for up to $310 million, which included $34.6 million upfront and contingent value rights tied to clinical and regulatory milestones for its diabetes program; this built on a 2018 collaboration with Lilly providing $63 million upfront plus potential milestones up to $410 million for exclusive global rights to SIG-002. Eli Lilly continues advancing SIG-002 through IND-enabling studies with a clinical trial application planned, while Sigilon's preclinical efforts focus on expanding SLTx applications to liver, immune-mediated, and other lysosomal diseases for patients with acute and chronic conditions worldwide.
Lilly Completes Acquisition of Sigilon Therapeutics
SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
Eli Lilly to buy Sigilon Therapeutics on a massive premium
Eli Lilly to Acquire Sigilon Therapeutics
Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?
Lilly to Acquire Sigilon Therapeutics
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
10 Best-Performing Penny Stocks in the Health Care Sector
Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates
Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates
Sigilon Therapeutics to Present at the Needham Healthcare Conference
Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
Bears are Losing Control Over Sigilon Therapeutics, Inc. (SGTX), Here's Why It's a 'Buy' Now
BMEZ: Buy Low, Hold For The Distribution And Rebound
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study